Abstract
This is a copy of an article published in the Cochrane Database of Systematic Reviews © 2016 Cochrane Collaboration Publications. © The Author(s). http://www.cochranelibrary.com/
Highlights
Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation
People already stabilised on oral risperidone may continue to maintain benefit if treated with depot risperidone and avoid the need to take tablets, at least in the short term
In people who are happy to take oral medication the depot risperidone is approximately equal to oral risperidone
Summary
Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation. Antipsychotic drugs are effective for treating acute episodes and for preventing relapse (Davis 1977; Davis 1986) These drugs are usually given orally, but compliance is poor and ranges from 20% to 89% with an average of 50% (Fenton 1997; Young 1986). This means that, on average, half the patients treated with these drugs will not comply with prescribed medication. This is probably due to a combination of various factors such as the erosion of insight that accompanies psychotic illnesses, adverse effects and human nature
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
